tuneTypical Dose
Fresh juice once daily for 1 month in the only meaningful RCT
Botanical
Wheatgrass
Triticum aestivum
Evidence TierDWADA NOT PROHIBITED
watchEffect Window
Measured over 1 month in ulcerative colitis.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Wheatgrass has a small randomized signal in active distal ulcerative colitis, but it is not a general detox or blood-building supplement.
Wheatgrass is marketed for detoxification, energy, and blood health, but the best human evidence is very limited. The main interventional signal is one small placebo-controlled trial in active distal ulcerative colitis using fresh wheatgrass juice. That finding is interesting but too narrow and small to justify broad claims.
Wheatgrass is usually discussed for antioxidant and chlorophyll-related effects, but clinical evidence is far too limited to support broad physiological claims.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Small signal for improvement in active distal ulcerative colitis
Secondary Outcomes
- Weak lipid-lowering signal in hyperlipidemic women
- No dependable evidence for detox or blood-health claims
Safety
Contraindications and Interactions
Contraindications
No entries provided
Side effects
- GI upset
Interactions
No entries provided
Avoid if
- You are using it instead of evidence-based ulcerative-colitis care
Evidence
Study-level References
whe-SRC-001Randomized controlled trial
Sourceopen_in_newBen-Arye E, et al. Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol. 2002. PMID:11989836.
Population: Adults with active distal ulcerative colitis.
Dose protocol: 100 mL fresh wheatgrass juice daily for 1 month
Key findings: Improved disease activity and rectal bleeding in active distal ulcerative colitis.
Notes: Only meaningful human RCT.
Paper content
This small trial is the main evidence anchor for wheatgrass. It showed improvement in active distal ulcerative colitis, but the evidence base is too small for broad claims.
whe-SRC-002Randomized controlled study
Sourceopen_in_newKulkarni SD, Tilak JC, Acharya R, Rajurkar NS, Devasagayam TPA, Reddy AVR. Impact of Wheatgrass (Triticum aestivum L.) Supplementation on Atherogenic Lipoproteins and Menopausal Symptoms in Hyperlipidemic South Asian Women - A Randomized Controlled Study. Maturitas. 2017;99:154-161. PMID:28121470.
Population: Fifty-nine hyperlipidemic South Asian women.
Dose protocol: 3.5 g/day freeze-dried wheatgrass powder for 10 weeks
Key findings: Lower total cholesterol, triglycerides, and Apo B versus control in hyperlipidemic women.
Notes: No placebo control and HDL also decreased, so the signal stays low confidence.
Paper content
This later wheatgrass trial suggests a possible lipid-lowering signal in hyperlipidemic women, but the design used a no-intervention control rather than a matched placebo and also showed an HDL reduction. That makes it a weak, context-specific metabolic signal rather than robust support for broad cardiometabolic claims.